Urine Drug Testing
Aspenti Health is home to state-of-the art laboratories in Vermont and Massachusetts that process urine drug screens in 24 hours, with a 48-hour turnaround for drug confirmations (Vermont lab only). Aspenti assists providers in creating customized patient-specific profiles to assist with patient care, along with providing guidance on medically necessary testing. Aspenti offers an extensive urine drug testing menu featuring over 70 drugs and metabolites.
The identification of these drugs, whether prescribed medications or illicit substances in urine, employs both presumptive screening methodologies (immunoassay and LC/MS-MS) and definitive chromatographic (LC/MS-MS) techniques to provide the best possible results for patient care.
Aspenti uses clinically validated and evidence-based cutoffs which follow industry standards to determine drug detection levels.
SPECIMEN VALIDITY TESTING
Specimen Validity Testing (SVT) is a form of specialized testing used to determine the specimen’s creatinine, specific gravity, pH and general oxidant levels. SVT provides insight into specimen tampering, adulteration or dilution. This testing, when combined with an observed collection, supports the patient through the treatment processes by helping to ensure the integrity of the specimen.
PRESUMPTIVE SCREENING: ENZYME IMMUNOASSAY (EIA)
EIA screening is routinely used as an initial step in urine drug testing services. This technology relies on antibodies to detect and semi-quantify specific drugs or drug classes, but can rarely be used to identify a specific drug or drug metabolite. All positive drug screens by EIA should be considered a presumptive or preliminary finding for the class of drugs tested. As clinically indicated, a follow up confirmatory method (such as LC-MS/MS) may be warranted.